KYTX

Kyverna Therapeutics Stock Analysis

AI Rating

Good
  • Quality2/10
  • Growth↓ 4/10
  • Value↑ 5/10
Kyverna Therapeutics sales and earnings growth
KYTX Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↓ 3.25%
  • FCF Y/Y↓ -11.94%
Kyverna Therapeutics gross and profit margin trends
KYTX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ 0.00%
Kyverna Therapeutics net debt vs free cash flow
KYTX Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -137.2

Kyverna Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks